Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) KRRO-110 is the first RNA editing oligonucleotide candidate from Korro’s proprietary OPERA™ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT)...

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...

Korro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer Tim Pearson, CEO of Carrick Therapeutics and ex-CFO of TESARO, will join as Director contingent on the close of the proposed merger with FrequencyTodd Chappell is elevated to role of Chief Operating...